natgillin/translations-raw huggingface dataset:
The median time to progression was 93 and 98 days.
Mediana časa do napredovanja bolezni je bila v prvem preskušanju 93, v drugem pa 98 dni.
A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of 500 mg two times daily.
Oseba, ki tehta 80 kg in je visoka 1,80 m, ima telesno površino 2,00 m2 in jemlje 5 tablet po 500 mg dvakrat na dan.
In human cancer xenograft models capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of thymidine phosphorylase by docetaxel.
V ksenografskih modelih raka pri ljudeh je imel kapecitabin v kombinaciji z docetakselom sinergistični učinek, kar je lahko povezano z uravnavanjem timidin fosforilaze zaradi docetaksela.
According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability of capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment.
Glede na farmakokinetično študijo pri bolnikih z rakom, ki imajo blago ali zmerno jetrno okvaro zaradi zasevkov v jetrih, je biološka uporabnost kapecitabina in izpostavljenost 5- FU lahko povečana v primerjavi z bolniki brez okvare.
In addition, during a 13-week study, atrophic and degenerative changes occurred in reproductive organs of male mice; however these effects were reversible after a drug-free period (see section 4.6).
Pri mišjih samcih pa so se v 13-tedenski študiji pojavile atrofične in degenerative spremembe na reproduktivnih organih, ki so po prenehanju jemanja kapecitabina izginile (glejte poglavje 4.6).
5-Fluorouracil 400 mg/m intravenous bolus, followed by 600 mg/ 2 intravenous 22 hr
5-fluorouracil 400 mg/m intravensko bolus, sledi 600 mg/m intravensko 22 h placebo ali bevacizumab
Based on a pharmacokinetic study in cancer patients with mild to severe renal impairment, there is no evidence for an effect of creatinine clearance on the pharmacokinetics of intact drug and 5-FU.
Glede na farmakokinetično študijo pri bolnikih, ki imajo blago do hudo ledvično okvaro, ni dokazov za vpliv kreatininskega očistka na farmakokinetiko zdravila in 5- FU.
Standard antidiarrhoeal treatments (e.g. loperamide) may be used.
Priporočljivo je standardno zdravljenje (npr. z loperamidom).
Table 5 lists ADRs associated with the use of capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3000 patients.
Preglednica 5 našteva neželene učinke, povezane z uporabo kapecitabina v kombinaciji z različnimi kemoterapijami pri več indikacijah, ki temeljijo na podatkih o varnosti, zbranih pri več kot 3.000
Film-coated tablet (tablet).
filmsko obložena tableta (tableta)
Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min [Cockcroft and Gault] at baseline).
Kapecitabin je kontraindiciran pri bolnikih s hudo ledvično okvaro (očistek kreatinina pod 30 ml/min (Cockcroft in Gault) na začetku zdravljenja).
If you take more Ecansya than you should, contact your doctor as soon as possible before taking the next dose.
Če ste vzeli večji odmerek zdravila Ecansya, kot bi smeli Če ste vzeli večji odmerek zdravila Ecansya, kot bi smeli, se takoj posvetujte z zdravnikom, še preden boste zaužili naslednjega.
Ecansya contains capecitabine, which itself is not a cytostatic medicine.
Zdravilo Ecansya vsebuje kapecitabin, ki sam nima citostatičnega učinka.
When capecitabine and cisplatin are used in combination, the use of vitamin B6 (pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of hand-foot syndrome, because of published reports that it may decrease the efficacy of cisplatin.
Kadar kapecitabin in cisplatin uporabljamo v kombinaciji, ni priporočljiva uporaba vitamina B6 (piridoksina) za simptomatično ali sekundarno profilaktično zdravljenje sindroma roka-noga.
If you stop taking Ecansya
Če ste prenehali jemati zdravilo Ecansya
- in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
- v kombinaciji z docetakselom (glejte poglavje 5.1) za zdravljenje bolnikov z lokalno napredovalo ali metastatsko obliko raka dojk po neuspešni citotoksični kemoterapiji.
In embryotoxicity and teratogenicity studies in mice, dose-related increases in foetal resorption and teratogenicity were observed.
V študijah o embriotoksičnosti in teratogenosti pri miših so opazili od odmerka odvisno povečanje odmrtja ploda in teratogenost.
5 mg/kg intravenous 30-90 mins
5 mg/kg intravensko 30-90 min
The elimination half-life (t1/2 in hours) of capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively.
Razpolovne dobe izločanja (t1/2 v urah) kapecitabina, 5'-DFCR, 5'-DFUR, 5-FU in FBAL so bile 0,85; 1,11; 0,66; 0,76 in 3,23.
Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m2/day).
Toksično delovanje na srce in ožilje (podaljšanje intervalov PR in QT) so opazili pri opicah cynomolgus po intravenskem dajanju (100 mg/kg), po večkratnem peroralnem dajanju (1.379 mg/m2/dan) pa ne.
HR (97.5% CI)
Razmerje ogroženosti (97,5 % CI)
In patients with unrecognised DPD deficiency treated with capecitabine as well as in those patients who test negative for specific DPYD variations, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9).
Pri bolnikih, pri katerih pomanjkanje DPD ni znano, kot tudi pri bolnikih z negativnim testom za specifične spremembe gena DPYD, ki jih zdravimo s kapecitabinom, se lahko pojavijo življenjsko ogrožujoče toksičnosti, ki se izrazijo kot akutno prekomerno odmerjanje (glejte poglavje 4.9).
The pooled analysis includes 3097 patients treated with capecitabine-containing regimens and 3074 patients treated with 5-FU-containing regimens.
Skupna analiza je zajela 3.097 bolnikov, katerih zdravljenje je vključevalo kapecitabin, in 3.074 bolnikov, katerih zdravljenje je vključevalo 5-FU.
The XELIRI has been compared with 5-FU + irinotecan (FOLFIRI) in three randomised studies in patients with metastatic colorectal cancer.
Shemo XELIRI so pri bolnikih z metastatskim kolorektalnim rakom primerjali s 5-FU + irinotekanom (FOLFIRI) v treh randomiziranih študijah.
Antacid: the effect of an aluminium hydroxide and magnesium hydroxide-containing antacid on the pharmacokinetics of capecitabine was investigated.
Antacid: Proučevali so vpliv antacida, ki vsebuje aluminijev hidroksid in magnezijev hidroksid, na farmakokinetiko kapecitabina.
Also, you need to be particularly careful if you are taking any of the following: - gout medicines (allopurinol), - blood-thinning medicines (coumarin, warfarin), - medicines for seizures or tremors (phenytoin), - interferon alpha, - radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab,
Posebno previdni morate biti tudi pri uporabi: - zdravil proti protinu (alopurinola), - zdravil proti strjevanju krvi (kumarinov, varfarina), - zdravil za preprečevanje epileptičnih napadov ali tremorja (fenitoina), - interferona alfa, - radioterapije in nekaterih zdravil za zdravljenje raka (folinske kisline, oksaliplatina,
ADRs are added according to the highest incidence seen in any of the major combination trials.
Neželeni učinki so dodani glede na največjo pogostnost, ki so jo opazili v katerem koli glavnem preskušanju s kombinacijo zdravil.
In vitro human plasma studies have determined that capecitabine, 5'-DFCR, 5'-DFUR and 5-FU are 54%, 10%, 62% and 10% protein bound, mainly to albumin.
Študije in vitro na človeški plazmi so pokazale, da se na proteine (v glavnem na albumin) veže 54 % kapecitabina, 10 % 5'-DFCR, 62 % 5'-DFUR in 10 % 5-FU.
During a treatment cycle for those toxicities considered by the treating physician not to be related to capecitabine, capecitabine should be continued and the dose of the other medicinal product should be adjusted according to the appropriate Prescribing Information.
Kadar se med ciklom zdravljenja pojavijo toksičnosti, za katere lečeči zdravnik meni, da niso povezane s kapecitabinom, je zdravljenje s kapecitabinom treba nadaljevati, odmerek drugega zdravila pa prilagoditi v skladu s primernim povzetkom glavnih značilnosti zdravila.
Children and adolescents Ecansya is not indicated in children and adolescents.
Zdravilo Ecansya ni namenjeno otrokom in mladostnikom.
If these side effects continue, however, contact your doctor immediately.
Če neželeni učinki ne izginejo, takoj pokličite zdravnika.
- metastatic colorectal cancer (see section 5.1).
- za zdravljenje metastatske oblike kolorektalnega raka (glejte poglavje 5.1).
If the patient becomes pregnant while receiving capecitabine, the potential hazard to the foetus must be explained.
Če bolnica med zdravljenjem s kapecitabinom zanosi, ji je treba razložiti možno tveganje za plod.
Parameter: Progression-free Survival EPP ITT Parameter: Overall Survival EPP ITT
Parameter: Preživetje brez napredovanja bolezni EPP ITT Parameter: Celokupno preživetje EPP ITT
The overall objective response rates in the all-randomised population (investigator assessment) were 25.7% (capecitabine) vs. 16.7% (Mayo regimen); p <0.0002.
Celokupen odgovor v randomiziranih skupinah (raziskovalčeva ocena) je bil 25,7 % (kapecitabin) v primerjavi s 16,7 % (shema Mayo); p < 0,0002.
If grade 2 or 3 hand-foot syndrome occurs, administration of capecitabine should be interrupted until the event resolves or decreases in intensity to grade 1.
Če se pojavi sindrom 2. ali 3. stopnje, je treba jemanje kapecitabina prekiniti, dokler simptomi ne ponehajo oziroma se ne zmanjšajo na 1. stopnjo.
Caution must be exercised in patients with diabetes mellitus or electrolyte disturbances, as these may be aggravated during capecitabine treatment.
Sladkorna bolezen ali elektrolitske motnje: Pri bolnikih s sladkorno boleznijo ali elektrolitskimi motnjami je potrebna previdnost, ker se njihovo stanje med zdravljenjem s kapecitabinom lahko poslabša.
Patients with certain heterozygous DPYD variants (including DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3 variants) have been shown to have increased risk of severe toxicity when treated with capecitabine.
Izkazalo se je, da imajo bolniki z določenimi heterozigotnimi različicami DPYD (vključno z različicami DPYD*2A, c.1679T>G, c.2846A>T in c.1236G>A/HapB3) pri zdravljenju s kapecitabinom večje tveganje za hudo toksičnost.
Capecitabine was not mutagenic in vitro to bacteria (Ames test) or mammalian cells (Chinese hamster V79/HPRT gene mutation assay).
Kapecitabin in vitro pri bakterijah (Amesov test) ali celicah sesalcev (kitajski hrček V79/HPRT, metoda genske mutacije) ni bil mutagen.
The median duration of survival was 10.5 months (capecitabine + cisplatin) versus 9.3 months (5-FU + cisplatin).
Mediana trajanja preživetja je bila 10,5 meseca (kapecitabin + cisplatin) v primerjavi z 9,3 meseca (5-FU + cisplatin).
Posology Recommended posology (see section 5.1):
Odmerjanje Priporočeno odmerjanje (glejte poglavje 5.1):
Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely and the anticoagulant dose adjusted accordingly (see section 4.5).
Bolnikom, ki sočasno prejemajo kapecitabin in peroralni kumarinski antikoagulant, je treba skrbno spremljati antikoagulantni odziv (INR ali protrombinski čas) ter ustrezno prilagajati odmerek antikoagulanta (glejte poglavje 4.5).
Currently, no comparative data are available on capecitabine monotherapy in colorectal cancer in comparison with first line combination regimens.
Trenutno še nimamo podatkov o primerjavi samostojnega zdravljenja s kapecitabinom s kombiniranim zdravljenjem v okviru prvega zdravljenja.
In the case of colorectal tumours, 5-FU generation appears to be in large part localised in tumour stromal cells.
Pri kolorektalnih tumorjih je generacija 5-FU močno lokalizirana v tumorskih stromalnih celicah.
Some of the ADRs are reactions commonly seen with the combination medicinal product (e.g. peripheral sensory neuropathy with docetaxel or oxaliplatin, hypertension seen with bevacizumab); however an exacerbation by capecitabine therapy cannot be excluded.
Nekatere neželene učinke pogosto opazijo pri zdravljenju z zdravilom iz kombinacije (npr. periferno senzorično nevropatijo pri docetakselu ali oksaliplatinu, hipertenzijo pri bevacizumabu); vseeno pa njihovega poslabšanja pri zdravljenju s kapecitabinom ne moremo izključiti.
XELOX or XELOX+ Bevacizumab
shema XELOX + bevacizumab
Radiotherapy: the MTD of capecitabine alone using the intermittent regimen is 3000 mg/m2 per day, whereas, when combined with radiotherapy for rectal cancer, the MTD of capecitabine is 2000 mg/m per day using either a continuous schedule or given daily Monday through Friday during a 6-week course of radiotherapy.
Radioterapija: Največji prenosljivi odmerek kapecitabina samega pri intermitentnem dajanju je 3.000 mg/m2 na dan, v kombinaciji z radioterapijo za rak danke pa je največji prenosljivi odmerek kapecitabina 2.000 mg/m2 na dan z uporabo neprekinjene sheme ali dnevnim dajanjem od ponedeljka do petka med 6-tedensko radioterapijo.
Thymidine phosphorylase activity was measured and found to be 4 times greater in primary colorectal tumour than in adjacent normal tissue.
Aktivnost timidin fosforilaze je štirikrat večja v primarnih kolorektalnih tumorjih kot v sosednjih zdravih tkivih.
Aluminium/aluminium or PVC/PVdC/aluminium blister containing 10 film-coated tablets.
Al/Al ali PVC/PVdC/Al pretisni omoti vsebujejo 10 filmsko obloženih tablet.
7.5 mg/kg intravenous 30-90 mins
7,5 mg/kg intravensko 30-90 min
In the EORTC study patients were randomised to receive either open label FOLFIRI (n=41) or XELIRI (n=44) with additional randomisation to either double-blind treatment with celecoxib or placebo.
V študiji EORTC so bolnike randomizirali, da so kot odprto zdravljenje prejeli FOLFIRI (n = 41) ali XELIRI (n = 44) in jih dodatno randomizirali v dvojno slepo zdravljenje s celekoksibom ali placebom.
Ecansya contains lactose
Zdravilo Ecansya vsebuje laktozo
Patients with severe diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated.
Driska: Bolnike, pri katerih se pojavi huda driska, je treba skrbno opazovati in jim v primeru dehidracije nadomeščati tekočino in elektrolite.
After oral administration, capecitabine is rapidly and extensively absorbed, followed by extensive conversion to the metabolites, 5'-DFCR and 5'-DFUR.
Po peroralnem zaužitju se kapecitabin absorbira hitro in v velikem obsegu, nato pa se v velikem obsegu pretvori v presnovka 5'-DFCR in 5'-DFUR.
Capecitabine dose reduction decreases systemic exposure to 5-FU more than dose-proportionally, due to non-linear pharmacokinetics for the active metabolite.
Če zmanjšamo odmerek kapecitabina, se sistemska izpostavljenost 5-FU zaradi nelinearne farmakokinetike aktivnega presnovka zmanjša bolj kot sorazmerno z odmerkom.
If grade 2 (or higher) dehydration occurs, capecitabine treatment should be immediately interrupted and the dehydration corrected.
Če se pojavi dehidracija stopnje 2 ali več, je treba zdravljenje s kapecitabinom takoj prekiniti in bolnika hidrirati.
MARKETING AUTHORISATION NUMBER (S)
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival in the eligible patient population and the intent-to-treat population (see table 7).
Ne-inferiornost zdravljenja, ki vsebuje XELOX v primerjavi z zdravljenjem, ki vsebuje FOLFOX-4 v celokupni primerjavi, je bila dokazana glede na preživetje brez napredovanja bolezni v primerni populaciji bolnikov in populaciji bolnikov, ki so jo nameravali zdraviti (glejte preglednico 7).
In addition to the above, when Ecansya is used alone, very common side effects, which may affect more than 1 in 10 people are: - abdominal pain - rash, dry or itchy skin - tiredness - loss of appetite (anorexia)
Poleg zgoraj omenjenih neželenih učinkov se lahko pri samostojni uporabi zdravila Ecansya zelo pogosto (pri več kot 1od 10 bolnikov) pojavijo naslednji neželeni učinki: - bolečina v trebuhu, - izpuščaj, suha ali srbeča koža, - utrujenost, - izguba apetita (anoreksija).
What Ecansya contains - The active substance is capecitabine.
Kaj vsebuje zdravilo Ecansya - Učinkovina je kapecitabin.
STOP taking Ecansya immediately and contact your doctor if any of these symptoms occur: - Diarrhoea: if you have an increase of 4 or more bowel movements compared to your normal bowel movements each day or any diarrhoea at night.
Če se pojavi kateri koli od navedenih simptomov, takoj PRENEHAJTE z jemanjem zdravila Ecansya in pokličite zdravnika: - Driska: če pogostnost dnevnih iztrebljanj preseže število, ki je za vas običajno, za štiri ali več, ali če imate ponoči drisko.
These adverse reactions may be more common in patients with a prior history of coronary artery disease.
Ti neželeni učinki so pogostejši pri bolnikih, ki so že imeli koronarno srčno bolezen.
Elderly.
Starejši
Median OS was 23.1 months for FOLFIRI, 17.6 months for mIFL (p=0.09), and 18.9 months for XELIRI (p=0.27).
Mediana celokupnega preživetja je bila 23,1 meseca za FOLFIRI, 17,6 meseca za mIFL (p = 0,09) in 18,9 meseca za XELIRI (p = 0,27).
Time to progressive disease was superior in the capecitabine + docetaxel combination arm (p<0.0001).
Čas do napredovanja bolezni je bil v skupini, ki je jemala kapecitabin in docetaksel, daljši (p < 0,0001).
In patients with mild renal impairment (creatinine clearance 51-80 ml/min at baseline) no adjustment of the starting dose is recommended.
Bolnikom z blago ledvično okvaro (očistek kreatinina 51 do 80 ml/min na začetku zdravljenja) začetnega odmerka ni treba prilagajati.
Following oral administration of capecitabine to patients with colorectal cancer, the ratio of 5-FU concentration in colorectal tumours to adjacent tissues was 3.2 (ranged from 0.9 to 8.0).
Po peroralnem zaužitju kapecitabina je pri bolnikih s kolorektalnim rakom razmerje koncentracij 5-FU v kolorektalnih tumorjih znašalo v primerjavi s sosednjimi tkivi 3,2 (območje 0,9 do 8,0).
Capecitabine is first metabolised by hepatic carboxylesterase to 5'-DFCR, which is then converted to 5-DFUR by cytidine deaminase, principally located in the liver and tumour tissues.
Kapecitabin se najprej pretvori z jetrno karboksilesterazo v 5'-DFCR, ta pa se prek citidin deaminaze, ki se nahaja v jetrih in tumorskih tkivih, naprej pretvori v 5'-DFUR.
DPD deficiency: if you have a known DPD deficiency, you are at an increased risk of acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by Ecansya (e.g. stomatitis, mucosal inflammation, diarrhoea, neutropenia, and neurotoxicity).
- Pomanjkanje DPD: če je znano, da imate pomanjkanje DPD, imate večje tveganje za nenaden, zgodnji pojav toksičnosti in hude, življenjsko ogrožujoče ali smrtne neželene učinke, povzročene z zdravilom Ecansya (npr. stomatitis, vnetje sluznic, drisko, nevtropenijo in nevrotoksičnost).
Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU).
Kapecitabin je necitotoksičen fluoropirimidinski karbamat v obliki prekurzorja citotoksične učinkovine 5-fluorouracila (5-FU).
Insufficient safety and efficacy data are available in patients with hepatic impairment to provide a dose adjustment recommendation.
Za bolnike z jetrno okvaro ni na razpolago dovolj podatkov o varnosti in učinkovitosti za navodila o prilagajanju odmerka.
ADRs considered by the investigator to be possibly, probably, or remotely related to the administration of capecitabine are listed in table 4 for capecitabine given as monotherapy and in table 5 for capecitabine given in combination with different chemotherapy regimens in multiple indications.
Neželeni učinki, ki so po mnenju raziskovalca morda, verjetno ali nejasno povezani z jemanjem kapecitabina, so navedeni v preglednici 4 za samostojno zdravljenje s kapecitabinom in v preglednici 5 za dajanje kapecitabina v kombinaciji z različnimi kemoterapijami pri več indikacijah.
The frequency of the heterozygous DPYD*2A genotype in the DPYD gene in Caucasian patients is around 1%, 1.1% for c.2846A>T, 2.6-6.3% for c.1236G>A/HapB3 variants and 0.07 to 0.1% for c.1679T>G.
Pri belcih je pogostnost heterozigotnega genotipa DPYD*2A v genu DPYD okoli 1 %, pogostnost različice c.2846A>T 1,1 %, različice c.1236G>A/HapB3 2,6-6,3 % in različice c.1679T>G 0,07-0,1 %.
Dose limiting toxicities
Toksičnosti, ki lahko omejijo odmerjanje
(neuropathy) - if you have calcium imbalances (seen in blood tests) - if you have diabetes - if you cannot keep food or water in your body because of severe nausea and vomiting - if you have diarrhoea - if you are or become dehydrated - if you have imbalances of ions in your blood (electrolyte imbalances, seen in tests) - if you have a history of eye problems as you may need extra monitoring of your eyes - if you have a severe skin reaction.
(nevropatijo)), - imate porušeno ravnovesje kalcija (opaženo pri krvni preiskavi), - imate sladkorno bolezen, - ne morete v sebi zadržati hrane ali tekočine zaradi hude slabosti in bruhanja, - imate drisko, - ste ali postanete dehidrirani, - imate porušeno ravnotežje ionov v vaši krvi (elektrolitsko neravnovesje, opaženo v preiskavah), - ste v preteklosti imeli bolezni oči, ker boste morda potrebovali dodatne kontrole oči, - imate hudo kožno reakcijo.
An effective method of contraception should be used during treatment and for 6 months after the last dose of capecitabine.
Med zdravljenjem in še 6 mesecev po zadnjem odmerku kapecitabina je treba uporabljati učinkovito metodo kontracepcije.
Maintain dose level
vzdrževanje odmerka vzdrževanje odmerka
Ophthalmologic complications: Patients should be carefully monitored for ophthalmological complications such as keratitis and corneal disorders, especially if they have a prior history of eye disorders.
Oftalmološki neželeni učinki: Bolnike je treba skrbno spremljati zaradi oftalmoloških neželenih učinkov, kot sta keratitis in okvare roženice, še posebej, če so v preteklosti že imeli bolezni oči.
For the dosing schedule of XELOX and FOLFOX-4 (without addition of placebo or bevacizumab), refer to table 6.
Odmerjanje zdravljenja po shemah XELOX in FOLFOX-4 (brez dodatka placeba ali bevacizumaba) je opisano v preglednici 6.
You must inform your doctor if you know that you have an allergy or over-reaction to this medicine, - if you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer medicines, such as fluorouracil), - if you are pregnant or breast-feeding, - if you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia or thrombocytopenia), - if you have severe liver or kidney problems, - if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD) - if you are being treated now or have been treated in the last 4 weeks with brivudine as part of herpes zoster (chickenpox or shingles) therapy.
Če imate preobčutljivostno reakcijo na to zdravilo, obvestite zdravnika, - če ste v preteklosti imeli hudo reakcijo na zdravljenje s fluoropirimidini (skupina zdravil za zdravljenje raka, kamor spada fluorouracil), - če ste noseči ali dojite, - če imate zelo nizko raven belih krvnih celic ali trombocitov v krvi (levkopenija, nevtropenija ali trombocitopenija), - če imate hude težave z jetri ali ledvicami, - če veste, da nimate nobene aktivnosti encima dihidropirimidin dehidrogenaze (DPD), - če se trenutno zdravite ali ste se v preteklih 4 tednih zdravili z brivudinom, ki se uporablja kot del zdravljenja herpes zostra (norice ali pasovec).
150 mg 300 mg 500 mg Dose per administration (mg)
150 mg 300 mg 500 mg Enkratni odmerek (mg)
Further catalytic activation of 5'-DFUR then occurs by thymidine phosphorylase (ThyPase).
Nadaljnja katalitska aktivacija 5'-DFUR poteka s timidin fosforilazo.